GT BIOPHARMA, INC. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GT BIOPHARMA, INC. stock issued during period, value, issued for services for the quarter ending 2025-12-31 was $0.00.
- GT BIOPHARMA, INC. stock issued during period, value, issued for services for the quarter ending 2025-09-30 was $0.00.
- GT BIOPHARMA, INC. stock issued during period, value, issued for services for the quarter ending 2025-06-30 was $718.00K.
- GT BIOPHARMA, INC. stock issued during period, value, issued for services for the quarter ending 2025-03-31 was $340.00K.
- GT BIOPHARMA, INC. stock issued during period, value, issued for services for fiscal 2025 was $718.00K, a 34.73% decline from fiscal 2024.
- GT BIOPHARMA, INC. stock issued during period, value, issued for services for fiscal 2024 was $1.10M, a 155.81% increase from fiscal 2023.
- GT BIOPHARMA, INC. stock issued during period, value, issued for services for fiscal 2023 was $430.00K.
- GT BIOPHARMA, INC. stock issued during period, value, issued for services for fiscal 2021 was $15.34M, a 5602.60% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $718.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2026-03-06 | $858.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $718.00K 10-Q · filed 2026-08-14 | $658.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $340.00K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $1.10M 10-K · filed 2025-02-21 |
| 2024-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $430.00K 10-K · filed 2025-02-21 |
| 2023-09-30 | $115.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | |
| 2023-03-31 | $315.00K 10-Q · filed 2024-05-15 | |
| 2022-09-30 | $1.20M 10-Q · filed 2023-11-01 | $8.70M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $390.00K 10-Q · filed 2023-08-07 | $7.83M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $872.00K 10-Q · filed 2023-05-15 | $7.76M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $6.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $15.34M 10-K · filed 2022-03-28 |
| 2021-09-30 | $327.00K 10-Q · filed 2022-10-31 | $9.20M derived: sum of 4 quarters · filed 2022-10-31 |
| 2021-06-30 | $327.00K 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $8.45M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | $269.00K 10-K · filed 2021-04-16 |
| 2019-12-31 | $5.31M 10-K · filed 2021-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |